Lightcast Announces Limited Commercial Release of Envisia™ Single-Cell Functional Analysis Platform for Antibody Discovery
'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB.
'The Lightcast Envisia platform is truly one of a kind, enabling us to analyze single-cell functional activity in real time,' said Toon Swings, PhD, Technology Expert at VIB. 'We are able to track cell behavior, administer treatments, and monitor responses over time, which helps identify and select cells of interest for downstream studies.'
While traditional single-cell analysis techniques often rely on genomic data to infer function, the Envisia platform uses droplet microfluidics to perform highly controlled, sequential single-cell functional assays that capture rich functional data sets to improve decision making. Built around Lightcast's proprietary light-controlled droplet manipulation technology, the platform enables parallel interrogation of tens of thousands of picoliter-scale droplets, offering unmatched precision and flexibility. By integrating functional screening early in the antibody discovery process, the Envisia platform allows researchers to select and advance the most promising candidates. It also opens new possibilities in cell-cell interaction studies and broader applications in immunology and oncology.
'The Lightcast team is excited to introduce Envisia to the scientific community at PEGS Boston and to highlight the cutting-edge work being done by our pharmaceutical and academic collaborators,' said Paul Loeffen, PhD, CEO of Lightcast. 'This limited product release marks a major milestone as we shift from technology development to customer-driven deployment. Researchers can secure their place now to gain a first-mover advantage and access to unprecedented functional insights that will power the next wave of innovative biologics and therapies.'
Featured PEGS Boston Presentations
Advances in Immunotherapy Luncheon
'Advancing Antibody Discovery with Single-Cell, Function-Focused Profiling'
Presenters:
Paul Loeffen, PhD, CEO of Lightcast
Kathrin Herbst, PhD, Director of Science at Lightcast
Poster Number: A60
Poster Presenter: Simon Margerison
Date/Time: May 12-13, 2025
As part of the limited release, Lightcast is working closely with leading pharmaceutical and academic institutions to validate performance, optimize protocols, and expand application areas, all in preparation for the launch of a diverse array of validated protocols later in 2025. The complete Envisia workflow will include advanced instrumentation, intelligent software, a purpose-built cartridge system, and assay kits optimized to a broad array of functional applications. The fully automated, end-to-end workflows will support a wide range of cell types, assay formats, and research applications. To learn more about the Envisia platform, visit www.lightcast.bio.
About Lightcast
Lightcast Discovery aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit www.lightcast.bio.
Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
a minute ago
- Business Wire
VASTHERA Receives U.S. FDA Clearance to initiate Phase 1 Clinical Trial of Pulmonary Arterial Hypertension Drug Candidate, VTB-10
SEOUL, South Korea--(BUSINESS WIRE)--On August 6, 2025, VASTHERA Co., Ltd. announced that it has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for VTB-10, its drug candidate for pulmonary arterial hypertension (PAH), a rare, life-threatening disease marked by elevated blood pressure in the lung arteries. VTB-10 is a first-in-class drug candidate developed using VASTHERA's proprietary Redoxizyme™ platform. VASTHERA identified a deficiency of the enzyme peroxiredoxin (PRX) in PAH lesions and developed VTB-10, a small molecule enzyme (Chemzyme) that precisely replicates PRX function. In preclinical studies, VTB-10 reversed abnormal vascular remodeling and restored functional endothelium. These dual effects clearly differentiate it from existing therapies. This milestone follows the FDA's designation of VTB-10 as an Orphan Drug (ODD) in November 2024, enabling VASTHERA to formally begin global clinical development. The program has been supported by national funding from the Korea Drug Development Fund (KDDF). Dr. Sang Wong Kang, Ph.D., CEO of VASTHERA, stated, 'The U.S. clinical entry of VTB-10 marks a major milestone, demonstrating VASTHERA's technological competitiveness in PAH treatment and reinforcing the global credibility of Korean biotech ventures. Through upcoming clinical trials, we aim to deliver an innovative treatment that can significantly improve quality of life for PAH patients.' Dr. Sang Wong Kang is an expert in redox regulation of cellular signaling since his early research at the NIH/NHLBI, has dedicated more than two decades to building the scientific foundation of the Redoxizyme™ platform. Since PRX deficiency is implicated in multiple diseases, this platform holds broad potential for developing novel therapeutics across various indications, supporting sustainable growth and long-term value creation in the global market. VASTHERA is building up its Redoxizyme™-based pipeline with VTB-10 as the cornerstone, and the initiation of the Phase 1 clinical study will mark a significant step in the evolution of its VASTHERA's pipeline portfolio with global potential.
Business Upturn
5 hours ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Wire
9 hours ago
- Business Wire
Technologent Partners with ITOCHU Techno-Solutions Corporation to Launch StageCrew in North America
IRVINE, Calif.--(BUSINESS WIRE)--StageCrew™ (Stage Crew), a cloud service that streamlines information collection and coordination in system operations and strengthens observability, will be provided in SaaS format by Technologent. This marks the first full-scale deployment in the United States of a Japan-developed cloud service independently created by ITOCHU Techno-Solutions Corporation. 'In Technologent, we have found a partner that not only shares this forward-looking perspective but has the proven capability to guide enterprises on their digital transformation journeys." 'We're thrilled to bring StageCrew to our customers as the North American service provider as part of our commitment to AI enabling our customers,' said Mike McLaughlin, CIO and Sr. Vice President of Professional Services at Technologent. 'By combining Technologent's deep expertise with StageCrew's AI-powered operational intelligence, we're not just solving problems—we're redefining how enterprises manage complexity and stay ahead of disruption.' "Our vision for StageCrew has always been to create an AI-transformed experience that moves IT operations from being reactive to proactive. A vision this ambitious cannot be realized alone,' said Nagaki Fujioka, Managing Executive Officer and COO, Digital Services Group, at ITOCHU Techno-Solutions Corporation. 'In Technologent, we have found a partner that not only shares this forward-looking perspective but has the proven capability to guide enterprises on their digital transformation journeys. Together, ITOCHU Techno-Solutions Corporation and Technologent are not simply selling software; we are building a new operational standard, powered by Multimodal AI and delivered through a partnership committed to tangible, transformative results for every client," continued Fujioka. Market Background In recent years, the need for accurate real-time system monitoring to ensure stable operations has increased significantly. However, using multiple tools for monitoring across many technology services, log collection and cross-discipline assessments has created significant challenges. These include time and labor-intensive coordination between departments and difficulties in aggregation and consolidation of information. This often complicates the identification of issues, root causes as well as establishing corrective action. In North America, the growing complexity of systems, driven by advancements in cloud-native solutions and microservices technologies, has heightened the demand for solutions that improve efficiency, reduce time-to-resolution and decrease manual effort. About StageCrew StageCrew is a cloud-based service developed by ITOCHU Techno-Solutions Corporation designed to enhance visibility and efficiency in system operations. It improves observability (the ability to monitor and understand system health) by integrating with a wide range of monitoring and log collection tools, providing a unified view of critical data across complex IT environments. By consolidating information and standardizing how incidents are handled, StageCrew helps IT teams respond to issues swiftly and consistently, ultimately improving service reliability. StageCrew empowers IT operations with a scalable, AI-enhanced platform that not only streamlines incident management but also promotes a culture of proactive monitoring and continuous improvement. In summary, StageCrew helps organizations run more resilient, observable, and efficient IT systems – ensuring that technology teams can respond faster, work smarter, and deliver more reliable services to the enterprise. Service Implementation Technologent will provide StageCrew in a SaaS model for the North American market delivered from a dedicated cloud infrastructure. Comprehensive support will be provided from pre-implementation consulting to design, PoC (Proof of Concept), and post-implementation support services to meet North American customer needs. Additional service and product engineering support will be provided to Technologent from ITOCHU Techno-Solutions Corporation, Japan. About Technologent Technologent is a women-owned, WBENC-certified and global provider of Information Technology solutions and services for Fortune 1000 companies. With our internationally recognized technical and sales team and well-established partnerships between the most cutting-edge technology brands, Technologent powers your business through a combination of foundational IT disciplines: Data, Security, Cloud and Artificial Intelligence. Together with Service Provider Solutions, Financial Services, Professional Services and our people, we're paving the way for your business operations with advanced problem-solving that isn't just reactive, but forward-thinking and future-proof. Technologent is a trademark of Thomas Gallaway Company, LLC dba Technologent in the United States and other jurisdictions.
